NCT04323306View on ClinicalTrials.gov

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

September 27, 2022

Study Completion Date

September 27, 2022

Conditions
Malaria
Interventions
DRUG

MMV688533

Investigational medicinal product

Trial Locations (1)

3004

Nucleus Network Corporate, Melbourne

Sponsors
All Listed Sponsors
collaborator

Nucleus Network Ltd

OTHER

collaborator

Southern Star Research

INDUSTRY

lead

Medicines for Malaria Venture

OTHER